Geneton developed a non-invasive method for obtaining important information about structural variation of a fetus based on a sample of maternal blood, called NIPT Test. The method does not pose any risk for the fetus or the mother, therefore represents safe alternative to traditionally used invasive methods.

The early version of NIPT Test released in 2015 was focuses on detection of whole chromosomal aneuploidies, primarily trisomy of chromosomes 13 (Patau syndrome), 18 (Edwars syndrome) and 21 (Down syndrome). Since then, Geneton team is making a huge effort to make the test more reliable and expand its limits to capture gonosomal and sub-chromosomal aberrations as well. As a result, 2 extended tests, have been released in 2017.